Verona Pharma

Verona Pharma plc is a United Kingdom-based bio-pharmaceutical company. The Company is engaged in developing drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Its program is RPL554, an inhaled, dual phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) inhibitors, as a nebulized treatment for patients in hospital with acute exacerbation of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. RPL554 has completed two double-blind placebo controlled randomized Phase II b studies of RPL554: one in mild to moderate asthma and another in mild to moderate COPD. Its other products include VRP700 and NAIPs. VRP700 is an anti-tussive (cough) drug and has completed a Phase II trial. The Company's subsidiaries include Rhinopharma Limited and Verona Pharma Inc.
Type
Public
HQ
London, GB
Size (employees)
11 (est)
Verona Pharma is headquartered in London, GB

Verona Pharma Office Locations

Verona Pharma has offices in London, Cardiff
London, GB
Cardiff, GB

Verona Pharma Metrics

Verona Pharma Summary

Market capitalization

£25.3 M

Closing share price

£1.26
Verona Pharma's current market capitalization is £25.3 M.

Verona Pharma Market Value History

We estimate that Verona Pharma's current employees are approximately 100% male

Verona Pharma Company Life

You may also be interested in